Rituximab- ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.

The article discusses the results of a retrospective cohort of patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), ineligible for radiation therapy, treated with the monoclonal antibody Rituximab and standard adriamycin, bleomycin, vinblastine, dacarbazine (ABVD). Topics covered include the effectivity and safety of combination drug therapy with Rituximab and ABVD, risk of pulmonary events, and Rituximab's use as a single agent in front-line therapy in advanced NLPHL.